Skip to content

Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events

Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01963949
Enrollment
0
Registered
2013-10-17
Start date
2013-10-31
Completion date
Unknown
Last updated
2014-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

To collect tumor tissue from patients with liver masses suspicious for primary liver cancer. The research biopsy will be used to identify biomarkers in future studies.

Detailed description

In this study patients are referred to the Department of Radiology for an image-guided (either CT or ultrasound) core needle biopsy of a liver mass suspicious for primary liver cancer as a part their clinical care. A written informed consent will be obtained for the clinical biopsy per standard protocol. Additional core biopsy of the liver mass will be performed for research purposes at the time of the clinical care biopsy. The additional research biopsy is not mandatory and is subject to a separate written informed consent, which will be obtained prior to the clinical biopsy.

Interventions

None listed

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Liver mass suspicious for primary liver cancer with a diagnostic liver biopsy planned as a part of clinical care 2. Age ≥ 18 years. 3. ECOG performance status 0-2 4. Adequate organ and marrow function as defined below: INR ≤ 1.5 platelets ≥ 70,000/mcl 5. Ability to understand and the willingness to sign a written informed consent 6. Target liver mass not subcapsular in nature as determined by the participating biopsy team 7. Child Pugh Turcotte score A or B

Exclusion criteria

1. Previous treatment for HCC 2. Any contraindication for clinical-care liver biopsy, including anti-coagulation therapy that cannot be discontinued prior to biopsy or large volume ascites

Design outcomes

Primary

MeasureTime frameDescription
Biopsy of Liver Masses5 yearsTo obtain tissue from biopsy of liver masses suspicious for primary liver cancer for use in future biomarker studies.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026